NCT07159373 Better Options for Lymphatic Filariasis Treatment
| NCT ID | NCT07159373 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Medicines Development for Global Health |
| Condition | Lymphatic Filariasis |
| Study Type | INTERVENTIONAL |
| Enrollment | 5,100 participants |
| Start Date | 2026-09-28 |
| Primary Completion | 2027-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 5,100 participants in total. It began in 2026-09-28 with a primary completion date of 2027-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn if mass drug administration with moxidectin in combination with diethylcarbamazine, and albendazole (MoxDA) can treat lymphatic filariasis, scabies and strongyloidiasis in children and adults living in communities where these diseases are common. The main questions it aims to answer are: 1. Does MoxDA clear infection in people with lymphatic filariasis ? 2. Does MoxDA cause any medical problems in infected and uninfected people? Researchers will compare MoxDA with ivermectin given together with diethylcarbamazine and albendazole (IDA) to see if it works better to clear infection and does not cause any more medical problems. Participants will: 1. Be tested to see if they are infected with the parasites that cause lymphatic filariasis, scabies and strongyloidiasis 2. Take 3 single doses of MoxDA or IDA, 12 months apart 3. Visit their village centre once or twice in the 1 week after each treatment for safety checkups
Eligibility Criteria
Inclusion Criteria: 1. Provision of signed and dated informed consent. 2. Resident in one of the study locations. Exclusion Criteria: There are no exclusion criteria to participation in the study. Treatment Exclusion Criteria: Participants are ineligible to receive the treatment regimen allocated to their village if they meet any of the following criteria: 1. Severe illness (any illness that is severe enough to interfere with activities of daily living); 2. Known or suspected allergy to ivermectin, moxidectin, diethylcarbamazine or albendazole; 3. Pregnant; 4. Breastfeeding a baby within 7 days of birth; 5. Age \< 4 years for villages randomised to moxidectin, diethylcarbamazine, and albendazole (MoxDA); or 6. Age \< 2 years or weight \< 15 kg for villages randomized to ivermectin, diethylcarbamazine and albendazole (IDA).
Frequently Asked Questions
Who can join the NCT07159373 clinical trial?
This trial is open to participants of all sexes, studying Lymphatic Filariasis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07159373 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 5,100 participants.
Is NCT07159373 currently recruiting?
Yes, NCT07159373 is actively recruiting participants. Visit ClinicalTrials.gov or contact Medicines Development for Global Health to inquire about joining.
Where is the NCT07159373 trial being conducted?
This trial is being conducted at Suva, Fiji.
Who is sponsoring the NCT07159373 clinical trial?
NCT07159373 is sponsored by Medicines Development for Global Health. The trial plans to enroll 5,100 participants.